HTPB effectively inhibits A549 xenograft growth without significant side effects.
(A) Balb/c nude mice bearing the established A549 tumors (∼50 mm3) were treated with HTPB via intraperitoneal (left panel) or oral administration (right panel) for three weeks (3 days/week). A known HDAC inhibitor, SAHA, was used for comparison in intraperitoneal experiments. The tumor volumes of mice were measured twice weekly. Points, mean; bars, ±SEM. Three mice per group for intraperitoneal injection and five mice per group for oral treatment were used in the xenograft experiment. (B) The tumor weights of mice were measured. P values were for comparisons with DMSO or vehicle control (* P<0.05, ** P<0.01). (C) HTPB treatments did not cause significant body weight loss of tested animals. (D) Hematological biochemistry tests including GOT, GPT, albumin and creatinine were examined and the results showed no significant differences between HTPB treatment and DMSO or solvent control.
